## INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/002307

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/192 A61K31/18 A61K31/63 A61K31/4402 A61K31/4406 A61K31/4409 A61K31/47 A61K31/381 A61K31/42 A61K31/426 A61K31/351 A61K31/445 A61P5/28 A61P25/24 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07C C07D G01N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, SCISEARCH, CANCERLIT, BEILSTEIN Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. 1-6, WO 01/36365 A (KARO BIO AB; MALM, JOHAN; Х LITTEN, CHRIS; APELOVIST, THERESA; HEDFORS,) 25 May 2001 (2001-05-25) 10-12 cited in the application page 5, paragraph 1 - page 6, last paragraph page 12, paragraph 2 - last paragraph examples 1-30,36-121 page 27, paragraph 2 - page 31, paragraph claims 1-15,17-19,22-25,32-36,38 -/--X Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents : T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention \*A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another ditation or other special reason (as specified) comment or particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Y" document of particular relevance; the claimed invention \*O\* document reforring to an oral disclosure, use, exhibition or other means "P" document published prior to the International filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 2 5. 10. 2005 5 July 2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel, (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Cielen, E



1	
	International Application No
	PCT/EP2005/002307

Calorani	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to dalm No.
Category *	Citation of document, with indication, where appropriate, or the relevant passages	helevant to dalii i vo.
X	WO 02/092550 A (KARO BIO AB; MALM, JOHAN; BRANDT, PETER; EDVINSSON, KARIN; ERICSSON, T) 21 November 2002 (2002-11-21) page 1, paragraph 1 page 3, paragraph 2 page 5, paragraph 2 - page 6, paragraph 2 page 11, paragraph 5 - page 12, paragraph 7 page 12, paragraph 10 - page 13, paragraph 1	1-6,9-12
	figure Scheme1 page 15, paragraph 1 page 16, paragraph 2 examples claims 1-7,9-13,16,17,22	
X	WO 01/36351 A (CORVAS INTERNATIONAL, INC; MADISON, EDWIN, L; BRUNCK, TERENCE, K; SEMP) 25 May 2001 (2001-05-25)	1,3-6, 9-12
Y	page 1, line 26 - page 2, line 2 page 4, line 25 - page 5, line 3 page 54, line 10 - page 58, line 15 page 92, lines 14-36 page 106, lines 24-40 claims 1,13-15,60,70-73 figures 1A-1G,1J,1K,1N,10,2I-2P,2S,2V	1,3-5
Υ	WO 02/34776 A (K.U.LEUVEN RESEARCH AND DEVELOPMENT; DECLERCK, PAUL; STASSEN, JEAN-MAR) 2 May 2002 (2002-05-02) page 9, line 31 - page 10, line 5	1,3-5
X	WO 2004/000789 A (ELI LILLY AND COMPANY; FERRITTO CRESPO, RAFAEL; MARTIN, JOSE, ALFREDO;) 31 December 2003 (2003-12-31) page 2, line 1 - page 5, line 21 page 9, lines 9-17 page 10, lines 12-20 page 29, lines 1-11 example 100	1,3-6,9, 11
X	FR 2 254 549 A (TAKEDA CHEMICAL, JA) 11 July 1975 (1975-07-11) page 1, lines 1-25 page 4, lines 13-17 examples 1.1-1.10,1.13-1.15,1.18-1.25,1.27,1.29,1.3 1,1.34 examples 1.38,1.54-1.57,3.2-3.4,5.2,6.1,6.4,9.1,10. 1 claims 1,17-31	1-3,6,9,



International Application No
PCT/EP2005/002307

3 June 1976 (1976-06-03) page 1, lines 5-9 page 2, lines 17-21 page 4, lines 16-26 compounds 19-31,39 claims 3,4,11  X US 4 080 505 A (KAWAMATSU ET AL) 21 March 1978 (1978-03-21) column 1, lines 1-32 compounds 11-16  X YOSHIOKA T ET AL: "STUDIES ON HINDERED PHENOLS AND ANALOGUES 1. HYPOLIPIDEMIC AND HYPOGLYCEMIC AGENTS WITH ABILITY TO INHIBIT LIPID PEROXIDATION" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 2, 1989, pages 421-428, XP002334138 ISSN: 0022-2623 abstract figure ChartVI; compound 25 figure SchemeII; compound 42 table III; compound 25 page 424, column 1, last paragraph - column 2, paragraph 4 page 424, column 2, last paragraph - page 425, column 1, paragraph 1 page 427, column 1, paragraphs 4,5			PC1/EP2003/002307	
X GB 1 437 781 A (BEECHAM GROUP LTD) 3 June 1976 (1976-06-03) page 1, lines 5-9 page 2, lines 17-21 page 4, lines 16-26 compounds 19-31,39 claims 3,4,11  X US 4 080 505 A (KAWAMATSU ET AL) 21 March 1978 (1978-03-21) column 1, lines 1-32 compounds 11-16  X YOSHIOKA T ET AL: "STUDIES ON HINDERED PHENOLS AND ANALOGUES 1. HYPOLIPIDEMIC AND HYPOGLYCEMIC AGENTS WITH ABILITY TO INHIBIT LIPID PEROXIDATION" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 2, 1989, pages 421-428, XPO02334138 ISSN: 0022-2623 abstract figure ChartVI; compound 25 figure Schemell; compound 42 table III; compound 25 page 424, column 1, last paragraph - column 2, paragraph 4 page 424, column 2, last paragraph - column 2, paragraph 4 page 427, column 1, paragraph 4 page 428, column 1, paragraph 4 page 429, column 1, paragraph 4 page 427, column 1, paragraph 4 page 428, column 1, paragraph 4 page 429, column 1, paragraph 4,5  X DATABASE WPI 20 December 1994 (1994-12-20), Derwent Publications Ltd., London, GB; Class 951,page 0, AN 1995-070268 XP002334142 OGAWA KAZUO; ONO TOMOYASU; YAMADA HARUO: "Urea derivative and its salt" & JP 06 345714 A (TAIHO PHARMACEUTICAL CO LTD) 20 December 1994 (1994-12-20) abstract	<u> </u>		Polovant to dolm No	
3 June 1976 (1976-06-03)   page 1, lines 5-9   page 2, lines 17-21   page 4, lines 16-26   compounds 19-31,39   claims 3,4,11	Category	Citation of document, with indication, where appropriate, or the relevant passages	Helevani to dami no.	
21 March 1978 (1978-03-21) column 1, lines 1-32 compounds 11-16  X YOSHIOKA T ET AL: "STUDIES ON HINDERED PHENOLS AND ANALOGUES 1. HYPOLIPIDEMIC AND HYPOGLYCEMIC AGENTS WITH ABILITY TO INHIBIT LIPID PEROXIDATION" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 2, 1989, pages 421-428, XP002334138 ISSN: 0022-2623 abstract figure ChartVI; compound 25 figure SchemeII; compound 42 table III; compound 25 page 424, column 1, last paragraph - column 2, paragraph 4 page 424, column 2, last paragraph - page 425, column 1, paragraph 1 page 427, column 1, paragraph 4,5  DATABASE WPI 20 December 1994 (1994-12-20), Derwent Publications Ltd., London, GB; Class 951,page 0, AN 1995-070268 XP002334142 OGAWA KAZUO; ONO TOMOYASU; YAMADA HARUO: "Urea derivative and its salt" & JP 06 345714 A (TAIHO PHARMACEUTICAL CO LTD) 20 December 1994 (1994-12-20) abstract	X	3 June 1976 (1976-06-03) page 1, lines 5-9 page 2, lines 17-21 page 4, lines 16-26 compounds 19-31,39	1,3,6,9, 11,12	
PHENOLS AND ANALOGUES 1. HYPOLIPIDEMIC AND HYPOGLYCEMIC AGENTS WITH ABILITY TO INHIBIT LIPID PEROXIDATION" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 2, 1989, pages 421-428, XP002334138 ISSN: 0022-2623 abstract figure ChartVI; compound 25 figure SchemeII; compound 42 table III; compound 25 page 424, column 1, last paragraph - column 2, paragraph 4 page 424, column 2, last paragraph - page 425, column 1, paragraph 1 page 427, column 1, paragraph 4,5  X DATABASE WPI 20 December 1994 (1994-12-20), Derwent Publications Ltd., London, GB; Class 951,page 0, AN 1995-070268 XP002334142 OGAWA KAZUO; ONO TOMOYASU; YAMADA HARUO: "Urea derivative and its salt" & JP 06 345714 A (TAIHO PHARMACEUTICAL CO LTD) 20 December 1994 (1994-12-20) abstract	X	21 March 1978 (1978-03-21) column 1, lines 1-32	1-3,6,9,	
20 December 1994 (1994-12-20), Derwent Publications Ltd., London, GB; Class 951,page 0, AN 1995-070268 XP002334142 OGAWA KAZUO; ONO TOMOYASU; YAMADA HARUO: "Urea derivative and its salt" & JP 06 345714 A (TAIHO PHARMACEUTICAL CO LTD) 20 December 1994 (1994-12-20) abstract	X	PHENOLS AND ANALOGUES 1. HYPOLIPIDEMIC AND HYPOGLYCEMIC AGENTS WITH ABILITY TO INHIBIT LIPID PEROXIDATION" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 2, 1989, pages 421-428, XP002334138 ISSN: 0022-2623 abstract figure ChartVI; compound 25 figure SchemeII; compound 42 table III; compound 25 page 424, column 1, last paragraph - column 2, paragraph 4 page 424, column 2, last paragraph - page 425, column 1, paragraph 1	1,3,6,9,	
	X	20 December 1994 (1994-12-20), Derwent Publications Ltd., London, GB; Class 951,page 0, AN 1995-070268 XP002334142 OGAWA KAZUO; ONO TOMOYASU; YAMADA HARUO: "Urea derivative and its salt" & JP 06 345714 A (TAIHO PHARMACEUTICAL CO LTD) 20 December 1994 (1994-12-20) abstract		



International Application No
PCT/EP2005/002307

	WALL DOCUMENTS CONCINCION TO BE DELEVANT	PC1/EP2005/00230/
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
Category *	Citation of occument, with indicaton, where appropriate, or the relevant passages	Tigiovani to significo.
X	KAWAMATSU Y ET AL: "STUDIES ON ANTIHYPERLIPIDEMIC AGENTS II. SYNTHESIS AND BIOLOGICAL ACTIVITIES OF 2-CHLORO-3-ARYLPROPIONIC ACIDS" ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 30, no. 4, 1980, pages 585-589, XP001146728 ISSN: 0004-4172 page 585, column 1, paragraph 1 - page 587, column 1, paragraph 2 table 1; compounds 12-22,24-25,32 table 3; compounds 65-72 table 4; compounds 34,38 page 587, column 2, paragraph 2 page 588, column 1, paragraph 1 page 588, column 2, last paragraph - page 589, column 1, paragraph 2	1-3,6,9,
Х	US 3 019 257 A (CANONICA LUIGI) 30 January 1962 (1962-01-30) examples II-IV claim 1	9,12
X	DEECHONGKIT SONGPON ET AL: "Synthesis of all nineteen appropriately protected chiral alpha-hydroxy acid equivalents of the alpha-amino acids for Boc solid-phase depsi-peptide synthesis."  ORGANIC LETTERS, vol. 6, no. 4, 19 February 2004 (2004-02-19), pages 497-500, XP002334139  ISSN: 1523-7060 figure 1 figures Scheme,1; compound 14	9
X	BUU-HOI N P ET AL: "ACIDES ARYLACETHYDROXAMIQUES ANTI-INFLAMMATOIRES ET ANALGESIQUES" CHIMICA THERAPEUTICA, SOCIETE D'ETUDES DE CHIMIE THERAPEUTIQUE, FR, vol. 2, no. 1, 1967, pages 39-48, XP000573817 table IIb	9



International Application No
PCT/EP2005/002307

No.



International Application No
PCT/EP2005/002307

TO THE THE CONSIDERED TO BE OF EVANT	10172720037002307
	Relevant to daim No.
Citation of document, with indication, where appropriate, or the relevant passages	Asisvalit to dailt no.
WO 2004/020420 A (F.HOFFMANN-LA ROCHE AG) 11 March 2004 (2004-03-11) page 1, lines 1-25 page 20, lines 1-12 figure Schemel; compounds 7-8 page 24, line 35 - page 25, line 13 examples 11,24,26-28,56,58,96,111 claim 1	1,3-6, 9-12
DATABASE WPI 21 May 2004 (2004-05-21), Derwent Publications Ltd., London, GB; Class 043,page 7, AN 2004-400532 XP002334143 FUKATSU K. ET AL.: "Receptor function controlling agent" & WO 2004/041266 A (TAKEDA CHEMICAL INDUSTRIES LTD) 21 May 2004 (2004-05-21) abstract	1-6,10,
-& WO 2004/041266 A (TAKEDA CHEMICAL INDUSTRIES, LTD; FUKATSU, KOHJI; SASAKI, SHINOBU; HINU) 21 May 2004 (2004-05-21) compounds 5-11,16,17,22-24,26,46-47,58-59,100-103,10 5-118 compounds 121,122,137-144,147,148,151,152,157,158,16 1,162 compounds 167,168,189,190,214,215,251,254,264-267	1-6,10,
WO 2005/009104 A (LIGAND PHARMACEUTICALS INCORPORATED; MAPES, CHRISTOPHER; KARANEWSKY, D) 3 February 2005 (2005-02-03) page 1, paragraph 2 compounds 1-11,13-23,26,29-33,35,39,58-59,61 page 57, paragraph 125 figure Scheme1 page 75, paragraph 169 examples 1-11,13-23,26,29-33,35,39,58,59,61,71,76-8 7,91,92 examples 101,102 claims 1,21,44,64	1-6,9-12
	11 March 2004 (2004-03-11) page 1, lines 1-25 page 20, lines 1-12 figure Schemel; compounds 7-8 page 24, line 35 - page 25, line 13 examples 11,24,26-28,56,58,96,111 claim 1  DATABASE WPI 21 May 2004 (2004-05-21), Derwent Publications Ltd., London, GB; Class 043,page 7, AN 2004-400532 XP002334143 FUKATSU K. ET AL.: "Receptor function controlling agent" & WO 2004/041266 A (TAKEDA CHEMICAL INDUSTRIES LTD) 21 May 2004 (2004-05-21) abstract -& WO 2004/041266 A (TAKEDA CHEMICAL INDUSTRIES, LTD; FUKATSU, KOHJI; SASAKI, SHINOBU; HINU) 21 May 2004 (2004-05-21) compounds 5-11,16,17,22-24,26,46-47,58-59,100-103,10 5-118 compounds 121,122,137-144,147,148,151,152,157,158,16 1,162 compounds 167,168,189,190,214,215,251,254,264-267  WO 2005/009104 A (LIGAND PHARMACEUTICALS INCORPORATED; MAPES, CHRISTOPHER; KARANEWSKY, D) 3 February 2005 (2005-02-03) page 1, paragraph 2 compounds 1-11,13-23,26,29-33,35,39,58-59,61 page 57, paragraph 125 figure SchemeI page 75, paragraph 169 examples 1-11,13-23,26,29-33,35,39,58,59,61,71,76-8 7,91,92 examples 101,102

International application No. PCT/EP2005/002307

# INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 4 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)
· This international Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:  .
·
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-6, 9-12
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

### 1. claims: 1-6, 9-12

A compound of formula (I) or (Ia) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester. amide or salt, for use in the treatment or prophylaxis of a condition mediated by an androgen receptor. A method for the treatment or prophylaxis of a condition in a mammal mediated by an androgen receptor, which comprises administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. Use of a compound of formula (I) or (Ia) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for the manufacture of a medicament for the treatment or prophylaxis of a condition mediated by an androgen receptor. A compound of formula (Ib) or (Ic) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. A compound of formula (Ib) or (Ic) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt for use as a medicament. A method for preparing a compound of formula (Ib) or (Ic).

#### 2. claim: 7

Use of a compound of formula (I) or (Ia) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, in labelled form as a diagnostic agent for the diagnosis of conditions associated with malfunction of the androgen receptor.

#### 3. claim: 8

A method of discovering a ligand of the androgen receptor which comprises the use of a compound of formula (I) or (Ia) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, or of such a compound in labelled form, as a reference compound.

# INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/002307

Information on patent family members

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0136365	Α	25-05-2001	AU	2666901 A	30-05-2001
WO 02092550	A	21-11-2002	CA CN DE EP JP US	2446747 A1 1509267 A 02735262 T1 1387825 A1 2004533450 T 2004220147 A1	21-11-2002 30-06-2004 08-07-2004 11-02-2004 04-11-2004 04-11-2004
WO 0136351	Α	25-05-2001	AU US	1624801 A 6677473 B1	30-05-2001 13-01-2004
WO 0234776	Α	02-05-2002	AU	1684702 A	06-05-2002
WO 2004000789	A	31-12-2003	AU CA CN EP	2003241579 A1 2488972 A1 1662487 A 1517882 A1	06-01-2004 31-12-2003 31-08-2005 30-03-2005
FR 2254549	A	11-07-1975	AU BE DE DK ES FI NL NO	7601874 A 823172 A1 2458375 A1 644374 A 432790 A1 357974 A 7416220 A 744352 A	03-06-1976 10-06-1975 19-06-1975 18-08-1975 16-02-1977 13-06-1975 16-06-1975 07-07-1975
GB 1437781	A	03-06-1976	AR AT AT BE BG CH CS DD ES FRU IL PL RO RO ZA	208269 A1 339301 B 286773 A 797715 A1 20352 A3 999868 A1 576961 A5 183689 B2 106834 A5 2316881 A1 413279 A1 2182933 A1 165731 B 37412 B1 41825 A 49100091 A 7304610 A 96043 B1 62274 A1 63069 A1 7301853 A	20-12-1976 10-10-1977 15-02-1977 03-10-1973 05-11-1975 16-11-1976 30-06-1976 31-07-1978 05-07-1974 11-10-1973 01-01-1976 14-12-1973 28-10-1974 20-07-1977 31-03-1977 20-09-1977 31-1977 15-12-1977 15-12-1977 15-08-1978 30-01-1974
US 4080505	A	21-03-1978	AU AU BE CA CH DE DK ES	500421 B2 1472676 A 842692 A1 1078403 A1 620414 A5 2625163 A1 251276 A 448647 A1	24-05-1979 15-12-1977 08-12-1976 27-05-1980 28-11-1980 30-12-1976 10-12-1977



Information on patent family members

International Application No PCT/EP2005/002307

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4080505 A		F1 761637 A FR 2333771 A1 GR 60269 A1 NL 7606250 A NO 761940 A PT 65179 A SE 7606441 A	10-12-1976 01-07-1977 20-04-1978 13-12-1976 10-12-1976 01-07-1976 10-12-1976
JP 6345714 A	20-12-1994	NONE	
US 3019257 A	30-01-1962	NONE	
EP 1471049 A	27-10-2004	CA 2473162 A1 WO 03064369 A1 US 2005085541 A1	07-08-2003 07-08-2003 21-04-2005
WO 03064369 A	07-08-2003	CA 2473162 A1 EP 1471049 A1 US 2005085541 A1	07-08-2003 27-10-2004 21-04-2005
WO 03071267 A	28-08-2003	AU 2003215315 A1 CA 2476761 A1 EP 1485709 A1	09-09-2003 28-08-2003 15-12-2004
WO 2004020420 A	11-03-2004	AU. 2003273801 A1 BR 0313946 A CA 2495942 A1 CN 1678596 A US 2004110807 A1	19-03-2004 12-07-2005 11-03-2004 05-10-2005 10-06-2004
WO 2004041266 A	21-05-2004	AU 2003277576 A1 CA 2505322 A1 EP 1559422 A1	07-06-2004 21-05-2004 03-08-2005
WO 2005009104 A	03-02-2005	NONE	